Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$27.87−1.17 (-4.03%)
Close on Nov 16, 2026Market cap $4.45BP/E –Yield –
Adaptive Biotechnologies total assets
Total assets on the balance sheet at the end of each period.
Adaptive Biotechnologies's total assets was $640.68M at Jun 30, 2026. For fiscal 2025 it was $512.74M, down 4.9% from the year before. The highest annual figure on record is $1.12B in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $512.74M | -4.9% |
| FY2024 | Dec 31, 2024 | $539.38M | -18.4% |
| FY2023 | Dec 31, 2023 | $661.13M | -22.8% |
| FY2022 | Dec 31, 2022 | $856.62M | -7.2% |
| FY2021 | Dec 31, 2021 | $923.34M | -17.3% |
| FY2020 | Dec 31, 2020 | $1.12B | +22.4% |
| FY2019 | Dec 31, 2019 | $912.30M | +174.2% |
| FY2018 | Dec 31, 2018 | $332.69M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $640.68M | +29.0% |
| Q1 FY2026 | Mar 31, 2026 | $505.94M | -1.0% |
| Q4 FY2025 | Dec 31, 2025 | $512.74M | -4.9% |
| Q3 FY2025 | Sep 30, 2025 | $490.61M | -12.2% |
| Q2 FY2025 | Jun 30, 2025 | $496.64M | -15.1% |
| Q1 FY2025 | Mar 31, 2025 | $510.85M | -17.6% |
| Q4 FY2024 | Dec 31, 2024 | $539.38M | -18.4% |
| Q3 FY2024 | Sep 30, 2024 | $558.51M | -22.2% |
| Q2 FY2024 | Jun 30, 2024 | $584.87M | -23.5% |
| Q1 FY2024 | Mar 31, 2024 | $620.32M | -21.6% |
| Q4 FY2023 | Dec 31, 2023 | $661.13M | -22.8% |
| Q3 FY2023 | Sep 30, 2023 | $717.68M | -18.8% |
| Q2 FY2023 | Jun 30, 2023 | $764.54M | -5.2% |
| Q1 FY2023 | Mar 31, 2023 | $791.46M | -7.8% |
| Q4 FY2022 | Dec 31, 2022 | $856.62M | -7.2% |
| Q3 FY2022 | Sep 30, 2022 | $884.21M | -10.9% |
| Q2 FY2022 | Jun 30, 2022 | $806.63M | -21.9% |
| Q1 FY2022 | Mar 31, 2022 | $858.19M | -20.0% |
| Q4 FY2021 | Dec 31, 2021 | $923.34M | -17.3% |
| Q3 FY2021 | Sep 30, 2021 | $992.61M | -9.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.03B | +20.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.07B | +22.5% |
| Q4 FY2020 | Dec 31, 2020 | $1.12B | +22.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.10B | +19.4% |
| Q2 FY2020 | Jun 30, 2020 | $854.82M | +42.1% |
| Q1 FY2020 | Mar 31, 2020 | $874.89M | +163.0% |
| Q4 FY2019 | Dec 31, 2019 | $912.30M | – |
| Q3 FY2019 | Sep 30, 2019 | $917.39M | – |
| Q2 FY2019 | Jun 30, 2019 | $601.40M | – |
| Q4 FY2018 | Dec 31, 2018 | $332.69M | – |
See a number that looks wrong?